Feeds:
Posts
Comments

Posts Tagged ‘Date certain’

Successful termination of “Prohibitive Executory Real Estate Contracts”

Posted in Board Of Intellectual Capital, boic, Distressed IP, Economy, Gerbsman Partners, Intellectual capital, Investments, Life Science, Strategy, Technology, Venture Capital, tagged , , , , , , , , , , , , , , , on June 4, 2009| Leave a Comment »

Steven R. Gerbsman, Principal of Gerbsman Partners, announced today that Gerbsman Partners successfully terminated the executory real estate contracts for two US based life science companies. The venture capital backed companies, executed leases for space in Northern, California. Due to market conditions, both companies made a strategic decision to terminate its corporate space allocation. Faced with potential contingent liabilities in excess of $ 6 million, the companies retained Gerbsman Partners to assist them in the termination of their prohibitive executory real estate contract.

About Gerbsman Partners

Gerbsman Partners focuses on maximizing enterprise value for stakeholders and shareholders in under-performing, under-capitalized and under-valued companies and their Intellectual Property. In the past 72 months, Gerbsman Partners has been involved in maximizing value for 52 Technology, Life Science and Medical Device companies and their Intellectual Property and has restructured/terminated over $780 million of real estate executory contracts and equipment lease/sub-debt obligations. Since inception, Gerbsman Partners has been involved in over $2.2 billion of financings, restructurings and M&A transactions.

Gerbsman Partners has offices and strategic alliances in Boston, New York, Washington, DC, Alexandria, VA, San Francisco, Europe and Israel.

For additional information please visit www.gerbsmanpartners.com

Read Full Post »

Fixing Israel’s Life Sciences Industry

Posted in Board Of Intellectual Capital, boic, Gerbsman Partners, Investments, Venture Capital, tagged , , , , , , , , , , , , , , , , , on March 2, 2009| 1 Comment »

Here is a good article from WSJ online by Jonathan Matsey.

The Israeli life science industry was in the spotlight recently, when Medtronic Inc. agreed to pay $325 million up-front for Netanya-based Ventor Technologies Ltd., which had raised $17 million in venture financing in part from Pitango Venture Capital. While the deal was great for Ventor’s investors, Rafi Hofstein, chairman of Hadasit Bio-Holdings Ltd., a publicly traded tech-transfer company for Jerusalem’s Hadassah University Hospital, said it highlights a problem with the country’s life science industry: the inability to develop home-grown companies to fruition. And despite the global economic downturn and the re-location of many of the country’s drug and device companies overseas, Hofstein said government policy – and a possible $240 million public-sponsored biotech fund – may ultimately reignite Israel’s life science industry.

Read the full article here

Read Full Post »

Successful Date Certain M&A of “Business Unit and Intellectual Property”

Posted in Uncategorized, tagged , , , , on January 20, 2009| Leave a Comment »

Steven R. Gerbsman, Principal of Gerbsman Partners and James Skelton, a member of Gerbsman Partners Board of Intellectual Capital, announced today their success in maximizing stakeholder value for a technology company that has been the leading provider of archival storage technology to the global IT market. Gerbsman Partners provided Crisis Management leadership, facilitated the sale of the business unit, associated Intellectual Property and assets and recovered substantial receivables. Due to market conditions, the senior lender made the strategic decision to maximize the value of the business unit and Intellectual Property. Gerbsman Partners provided leadership to the company with:

  • Crisis Management and Technology experience in developing the strategic action plans for maximizing value of the business unit, Intellectual Property and assets;
  • Proven domain expertise in maximizing the value of the business unit and Intellectual Property through a targeted and proprietary Date Certain M&A plan;
  • The ability to “Manage the Process” among potential Acquirers, Lawyers, Creditors Management and Advisors;
  • The proven ability to “Drive” toward successful closure for all parties at interest.

About Gerbsman Partners

Gerbsman Partners focuses on maximizing enterprise value for stakeholders and shareholders in under-performing, under-capitalized and under-valued companies and their Intellectual Property. In the past 60 months, Gerbsman Partners has been involved in maximizing value for 51 Technology, Life Science and Medical Device companies and their Intellectual Property and has restructured/terminated over $770 million of real estate executory contracts and equipment lease/sub-debt obligations. Since inception, Gerbsman Partners has been involved in over $2.2 billion of financings, restructurings and M&A transactions.

Gerbsman Partners has offices and strategic alliances in Boston, New York, Washington, DC, San Francisco, Europe and Israel.

For more information, please contact: Steve@GerbsmanPartners.com

Read Full Post »

« Newer Posts